Mar 18, 2014 7:00am EDT NeoGenomics Announces Next Generation Sequencing Tests for Solid Tumor Cancers and Myelodysplastic Syndrome
Feb 19, 2014 7:00am EST NeoGenomics Reports Record Revenue of $18.3 Million, Adjusted EBITDA of $2.7 Million and Net Income of $0.02 per Share for the Fourth Quarter 2013
Jan 30, 2014 7:00am EST NeoGenomics Launches 22 New Cancer Genomic Tests Designed for Actionable Profiling of Various Hematologic and Solid Cancers
Jan 17, 2014 2:20pm EST NeoGenomics Schedules its Q4 2013 and Full Year 2013 Earnings Release for February 19, 2014
